Clinical trials: Advanced Malignant Tumor
Advanced Malignant Tumor
A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
The primary objective is to determine the safety and tolerability of SH3765 in subjects with advanced malignant tumor by determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
- Trial name
- NCT05015309
- Testing
- SH3765 tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Recurrent Melanoma, Stage III Skin Melanoma
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
This phase II trial is studying how well giving bevacizumab together with sorafenib works in treating patients with unresectable stage III or stage IV malignant melanoma.
- Conditions
- Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- NCT00387751
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT00293345
- Testing
- gemcitabine hydrochloride, triapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
A phase1 study to evaluate the PK (single dose and multiple doses) and safety of talazoparib 1 mg Once Daily in Chinese adult participants with advanced solid tumors.
- Trial name
- NCT04635631
- Testing
- talazoparib
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Pfizer
Advanced Breast Cancer
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a…
- Trial name
- SERENA-1b (NCT07427394)
- Testing
- Camizestrant, Atirmociclib
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Lymphoma
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies
This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.
- Trial name
- NEON-1 (NCT04186637)
- Testing
- ALPN-202
- Where
- 10 sites in United States, Australia
- Volunteers
- 62 people
- Sponsor
- Alpine Immune Sciences, Inc.
Solid Tumour
Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors
This is a two-part, Phase 1 open label, single-center, dose escalation study of KHK2898 as monotherapy in subjects with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available.
- Trial name
- NCT01516645
- Testing
- KHK2898
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Solid Tumor
A Study of LY3415244 in Participants With Advanced Solid Tumors
The goal of this study is to evaluate the safety of LY3415244, a PD-L1/TIM-3 bispecific antibody, administered as monotherapy to participants with advanced solid tumors.
- Trial name
- NCT03752177
- Testing
- LY3415244
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Advanced Gastrointestinal Stromal Tumors
Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
The treatment of advanced GIST patients is based on imatinib followed with sunitinib in case of resistance/intolerance. However, the median progression-free survival (PFS) on sunitinib is frequently short, and after failure with…
- Trial name
- CYCLIGIST (NCT01907607)
- Testing
- PD 0332991
- Where
- 9 sites in France
- Volunteers
- 29 people
- Sponsor
- Institut Bergonié
Advanced Malignancies
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI939 in subjects with advanced malignancies
- Trial name
- NCT04353830
- Testing
- IBI939, IBI939+ Sintilimab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Malignant Fungating Wound
Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
This is a first-in-human, single-arm, open-label, dose escalating study to determine the safety and the recommended maximum tolerated dose of the AMT in subjects with malignant cutaneous lesions.
- Trial name
- NCT04807257
- Testing
- Auger Molecular Therapy (AMT)
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- NanoRay Biotech Co., Ltd.
Advanced Cancer
Treatment of Carrying TP53 Harmful Mutations
Assessment of the safety and tolerability of Fluzoparib combined with Apatinib in the treatment of advanced refractory solid tumors with TP53 harmful mutations.
- Trial name
- NCT03645200
- Testing
- Fluzoparib combined with Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Second Hospital
Solid Tumor, Adult, Metastasis
Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer
The purpose of the randomized control trial is to estimate the effect of an oncology clinical nurse specialist-led early intervention multidisciplinary approach to palliative and survivorship care within two previously identified…
- Trial name
- NCT05947695
- Testing
- Palliative and Survivorship Care Model
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Good Samaritan Hospital Medical Center, New York
Malignant Melanoma
PET Imaging of the Immune System Using Analog Probes
The goal of this proposal is to assess the biodistribution of 18F-Clofarabine, a new tracer developed for use in PET/CT scans. The investigator's hypothesis is this tracer will allow for imaging immune activation in patients with…
- Trial name
- NCT03409419
- Testing
- [18F] CFA
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Locally Advanced Malignant Neoplasm, Gastric Cancer
Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer
The purpose of this study is to determine safety and feasibility of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in patients with locally advanced gastric cancer undergoing standard…
- Trial name
- NCT02672865
- Testing
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Loma Linda University
Unspecified Adult Solid Tumor, Protocol Specific
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
RATIONALE: Vatalanib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vatalanib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00390000
- Testing
- vatalanib, pemetrexed disodium, pharmacological study
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Pancreatic Neuroendocrine Tumors (pNET)
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
This is a Phase II study in 2 stages, evaluating BEZ235 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy.
- Trial name
- NCT01658436
- Testing
- BEZ235 (Stage 1)
- Where
- 17 sites in United States, Austria and 7 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
PR-104 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00349167
- Testing
- PR-104, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Proacta, Incorporated
Lymphoma
Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells.
- Trial name
- NCT00002618
- Testing
- filgrastim, cytarabine, doxorubicin hydrochloride
- Where
- 10 sites in United States, Puerto Rico and 1 more
- Volunteers
- 242 people
- Sponsor
- Children's Oncology Group
Solid Tumor, Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
This is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and…
- Trial name
- METZOLIMOS (NCT02517918)
- Testing
- Sirolimus combined with CP, MT and ZA
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Institut Bergonié
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.